jofinЖурнал инфектологииJournal Infectology2072-6732IPO “АIDSSPbR"10.22625/2072-6732-2023-15-4-35-41jofin-1565Research ArticleОбзорReviewСовременные подходы к иммунотерапии инфекции Clostridioides difficileModern approaches to the immunotherapy of Clostridioides difficileПопругаК. Э.PoprugaK. E.

Попруга Катерина Эдуардовна – аналитик 2-й категории отдела анализа и прогнозирования медико-биологических рисков здоровью; тел.:  8(495)540-61-75 доб. 4517

Москва

Moscow

KPopruga@cspfmba.ruМакаровВ. В.MakarovV. V.

Макаров Валентин Владимирович – заместитель  директора Института синтетической биологии и генной инженерии по научно-экспериментальной работе, к.б.н.; тел.: 8(495)540-61-75 доб. 4004

Москва

Moscow

Makarov@cspfmba.ruЦентр стратегического планирования и управления медико-биологическими рисками здоровьюРоссияCentre for Strategic Planning and Management of Biomedical Health RisksRussian Federation2023100120241543541Copyright © Попруга К.Э., Макаров В.В., 20242024Попруга К.Э., Макаров В.В.Popruga K.E., Makarov V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.niidi.ru/jofin/article/view/1565

Clostridioides difficile является основной причиной диареи и псевдомембранозного колита, ассоциированных с терапией антибиотиками. Гипервирулентные штаммы C. difficile, такие как риботип 027, характеризуются высоким уровнем смертности. Рецидивирующая инфекция C. difficile крайне трудно поддается лечению. Симптомы заболевания провоцируют 2 токсина, TcdA и TcdB. Эти токсины являются мишенями для терапевтических антител. Одобренное для профилактики рецидивирующей инфекции C. difficile моноклональное антитело безлотоксумаб (Zinplava ©, Merck & Co. Inc., США), специфичное к TcdB, обладает определенной эффективностью в отношении ограниченного набора штаммов C. difficile. Обладая меньшей по сравнению с моноклональными антителами себестоимостью, высокой аффинностью к антигену и уникальными структурно-функциональными свойствами, наноантитела являются перспективной стратегией иммунотерапии заболеваний, связанных с C. difficile.

Clostridioides difficile is a leading cause of diarrhea and pseudomembranous colitis associated with antibiotic therapy. Hypervirulent strains of C. difficile, such as ribotype 027, have high mortality rates. Recurrent C. difficile infection is extremely difficult to treat. Symptoms of the disease are caused by two toxins, TcdA and TcdB. These toxins are targets for therapeutic antibodies. The TcdB-specific monoclonal antibody bezlotoxumab (Zinplava ©, Merck & Co. Inc., USA), approved for the prevention of recurrent C. difficile infection, has some effectiveness against a limited set of C. difficile strains. Having a lower cost compared to monoclonal antibodies, high affinity for the antigen, and unique structural and functional properties, nanoantibodies are a promising strategy for the immunotherapy of diseases associated with C. difficile.

Clostridioides difficileTcdATcdBиммунотерапиямоноклональные антителабезлотоксумабнаноантителаClostridioides difficileTcdATcdBimmunotherapymonoclonal antibodiesbezlotoxumabnanobodiesReferencesBuddle J.E., Fagan R.P. Pathogenicity and virulence of Clostridioides difficile // Virulence. 2023. Vol. 14, № 1.Buddle J.E., Fagan R.P. Pathogenicity and virulence of Clostridioides difficile // Virulence. 2023. Vol. 14, № 1.Hota S.S. et al. Determining Mortality Rates Attributable to Clostridium difficile Infection // Emerg. Infect. Dis. 2012. Vol. 18, № 2. P. 305–307.Hota S.S. et al. Determining Mortality Rates Attributable to Clostridium difficile Infection // Emerg. Infect. Dis. 2012. Vol. 18, № 2. P. 305–307.Czepiel J. et al. Clostridium difficile infection: review // Eur. J. Clin. Microbiol. Infect. Dis. 2019. Vol. 38, № 7. P. 1211–1221.Czepiel J. et al. Clostridium difficile infection: review // Eur. J. Clin. Microbiol. Infect. Dis. 2019. Vol. 38, № 7. P. 1211–1221.Dobson G., Hickey C., Trinder J. Clostridium difficile colitis causing toxic megacolon, severe sepsis and multiple organ dysfunction syndrome // Intensive Care Med. 2003. Vol. 29, № 6. P. 1030–1030.Dobson G., Hickey C., Trinder J. Clostridium difficile colitis causing toxic megacolon, severe sepsis and multiple organ dysfunction syndrome // Intensive Care Med. 2003. Vol. 29, № 6. P. 1030–1030.Guery B. Clostridium difficile infection trials: what is the primary endpoint? // Lancet Infect. Dis. 2019. Vol. 19, № 3. P. 219–220.Guery B. Clostridium difficile infection trials: what is the primary endpoint? // Lancet Infect. Dis. 2019. Vol. 19, № 3. P. 219–220.Bartlett J.G. Narrative Review: The New Epidemic of Clostridium difficile –Associated Enteric Disease // Ann. Intern. Med. 2006. Vol. 145, № 10. P. 758.Bartlett J.G. Narrative Review: The New Epidemic of Clostridium difficile –Associated Enteric Disease // Ann. Intern. Med. 2006. Vol. 145, № 10. P. 758.Marra A.R. et al. Incidence and Outcomes Associated With Clostridium difficile Infections // JAMA Netw. Open. 2020. Vol. 3, № 1. P. e1917597.Marra A.R. et al. Incidence and Outcomes Associated With Clostridium difficile Infections // JAMA Netw. Open. 2020. Vol. 3, № 1. P. e1917597.Hall A.J. et al. The Roles of Clostridium difficile and Norovirus Among Gastroenteritis-Associated Deaths in the United States, 1999–2007 // Clin. Infect. Dis. 2012. Vol. 55, № 2. P. 216–223.Hall A.J. et al. The Roles of Clostridium difficile and Norovirus Among Gastroenteritis-Associated Deaths in the United States, 1999–2007 // Clin. Infect. Dis. 2012. Vol. 55, № 2. P. 216–223.Dubberke E.R., Olsen M.A. Burden of Clostridium difficile on the Healthcare System // Clin. Infect. Dis. 2012. Vol. 55, № suppl_2. P. S88–S92.Dubberke E.R., Olsen M.A. Burden of Clostridium difficile on the Healthcare System // Clin. Infect. Dis. 2012. Vol. 55, № suppl_2. P. S88–S92.Филь Т.С. Стратификация факторов риска развития антибиотикоассоциированной диареи: автореф. дис. ... канд. наук 2017.Fil’ T.S. Stratifikaciya faktorov riska razvitiya antibiotikoassociirovannoj diarei: avtoref. dis. ... kand. nauk 2017.Nikolaeva I. V. et al. Clostridioides (Clostridium) difficile infection. Review of current clinical guidelines // Pract. Med. 2020. Vol. 18, № 6. P. 106–112.Nikolaeva I. V. et al. Clostridioides (Clostridium) difficile infection. Review of current clinical guidelines // Pract. Med. 2020. Vol. 18, № 6. P. 106–112.Hensgens M.P.M. et al. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics // J. Antimicrob. Chemother. 2012. Vol. 67, № 3. P. 742–748.Hensgens M.P.M. et al. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics // J. Antimicrob. Chemother. 2012. Vol. 67, № 3. P. 742–748.Theriot C.M., Young V.B. Interactions Between the Gastrointestinal Microbiome and Clostridium difficile // Annu. Rev. Microbiol. 2015. Vol. 69, № 1. P. 445–461.Theriot C.M., Young V.B. Interactions Between the Gastrointestinal Microbiome and Clostridium difficile // Annu. Rev. Microbiol. 2015. Vol. 69, № 1. P. 445–461.Theriot C.M. et al. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection // Nat. Commun. 2014. Vol. 5, № 1. P. 3114.Theriot C.M. et al. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection // Nat. Commun. 2014. Vol. 5, № 1. P. 3114.Owens, Jr. R.C. et al. Antimicrobial-Associated Risk Factors for Clostridium difficile Infection // Clin. Infect. Dis. 2008. Vol. 46, № s1. P. S19–S31.Owens, Jr. R.C. et al. Antimicrobial‐Associated Risk Factors for Clostridium difficile Infection // Clin. Infect. Dis. 2008. Vol. 46, № s1. P. S19–S31.Surawicz C.M. et al. Guidelines for Diagnosis, Treatment, and Prevention of Clostridium difficile Infections // Am. J. Gastroenterol. 2013. Vol. 108, № 4. P. 478–498.Surawicz C.M. et al. Guidelines for Diagnosis, Treatment, and Prevention of Clostridium difficile Infections // Am. J. Gastroenterol. 2013. Vol. 108, № 4. P. 478–498.Debast S.B., Bauer M.P., Kuijper E.J. European Society of Clinical Microbiology and Infectious Diseases: Update of the Treatment Guidance Document for Clostridium difficile Infection // Clin. Microbiol. Infect. 2014. Vol. 20. P. 1–26.Debast S.B., Bauer M.P., Kuijper E.J. European Society of Clinical Microbiology and Infectious Diseases: Update of the Treatment Guidance Document for Clostridium difficile Infection // Clin. Microbiol. Infect. 2014. Vol. 20. P. 1–26.McFarland L. V. et al. Recurrent Clostridium Difficile Disease: Epidemiology and Clinical Characteristics // Infect. Control Hosp. Epidemiol. 1999. Vol. 20, № 01. P. 43–50.McFarland L. V. et al. Recurrent Clostridium Difficile Disease: Epidemiology and Clinical Characteristics // Infect. Control Hosp. Epidemiol. 1999. Vol. 20, № 01. P. 43–50.Ghantoji S.S. et al. Economic healthcare costs of Clostridium difficile infection: a systematic review // J. Hosp. Infect. 2010. Vol. 74, № 4. P. 309–318.Ghantoji S.S. et al. Economic healthcare costs of Clostridium difficile infection: a systematic review // J. Hosp. Infect. 2010. Vol. 74, № 4. P. 309–318.Kuehne S.A. et al. The role of toxin A and toxin B in Clostridium difficile infection // Nature. 2010. Vol. 467, № 7316. P. 711–713.Kuehne S.A. et al. The role of toxin A and toxin B in Clostridium difficile infection // Nature. 2010. Vol. 467, № 7316. P. 711–713.Aktories K. Bacterial protein toxins that modify host regulatory GTPases // Nat. Rev. Microbiol. 2011. Vol. 9, № 7. P. 487–498.Aktories K. Bacterial protein toxins that modify host regulatory GTPases // Nat. Rev. Microbiol. 2011. Vol. 9, № 7. P. 487–498.Pruitt R.N. et al. Structural organization of the functional domains of Clostridium difficile toxins A and B // Proc. Natl. Acad. Sci. 2010. Vol. 107, № 30. P. 13467–13472.Pruitt R.N. et al. Structural organization of the functional domains of Clostridium difficile toxins A and B // Proc. Natl. Acad. Sci. 2010. Vol. 107, № 30. P. 13467–13472.Kordus S.L., Thomas A.K., Lacy D.B. Clostridioides difficile toxins: mechanisms of action and antitoxin therapeutics // Nat. Rev. Microbiol. 2022. Vol. 20, № 5. P. 285–298.Kordus S.L., Thomas A.K., Lacy D.B. Clostridioides difficile toxins: mechanisms of action and antitoxin therapeutics // Nat. Rev. Microbiol. 2022. Vol. 20, № 5. P. 285–298.Chen P. et al. Structural basis for CSPG4 as a receptor for TcdB and a therapeutic target in Clostridioides difficile infection // Nat. Commun. 2021. Vol. 12, № 1. P. 3748.Chen P. et al. Structural basis for CSPG4 as a receptor for TcdB and a therapeutic target in Clostridioides difficile infection // Nat. Commun. 2021. Vol. 12, № 1. P. 3748.Kyne L. et al. Asymptomatic Carriage of Clostridium difficile and Serum Levels of IgG Antibody against Toxin A // N. Engl. J. Med. 2000. Vol. 342, № 6. P. 390–397.Kyne L. et al. Asymptomatic Carriage of Clostridium difficile and Serum Levels of IgG Antibody against Toxin A // N. Engl. J. Med. 2000. Vol. 342, № 6. P. 390–397.Kyne L. et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea // Lancet. 2001. Vol. 357, № 9251. P. 189–193.Kyne L. et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea // Lancet. 2001. Vol. 357, № 9251. P. 189–193.Leav B.A. et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI) // Vaccine. 2010. Vol. 28, № 4. P. 965–969.Leav B.A. et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI) // Vaccine. 2010. Vol. 28, № 4. P. 965–969.Raeisi H. et al. Application of recombinant antibodies for treatment of Clostridioides difficile infection: Current status and future perspective // Front. Immunol. 2022. Vol. 13.Raeisi H. et al. Application of recombinant antibodies for treatment of Clostridioides difficile infection: Current status and future perspective // Front. Immunol. 2022. Vol. 13.Wilcox M.H. et al. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection // N. Engl. J. Med. 2017. Vol. 376, № 4. P. 305–317.Wilcox M.H. et al. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection // N. Engl. J. Med. 2017. Vol. 376, № 4. P. 305–317.Rupnik M. Heterogeneity of large clostridial toxins: importance of Clostridium difficile toxinotypes // FEMS Microbiol. Rev. 2008. Vol. 32, № 3. P. 541–555.Rupnik M. Heterogeneity of large clostridial toxins: importance of Clostridium difficile toxinotypes // FEMS Microbiol. Rev. 2008. Vol. 32, № 3. P. 541–555.Shen E. et al. Subtyping analysis reveals new variants and accelerated evolution of Clostridioides difficile toxin B // Commun. Biol. 2020. Vol. 3, № 1. P. 347.Shen E. et al. Subtyping analysis reveals new variants and accelerated evolution of Clostridioides difficile toxin B // Commun. Biol. 2020. Vol. 3, № 1. P. 347.Hernandez L.D. et al. Broad Coverage of Genetically Diverse Strains of Clostridium difficile by Actoxumab and Bezlotoxumab Predicted by In Vitro Neutralization and Epitope Modeling // Antimicrob. Agents Chemother. 2015. Vol. 59, № 2. P. 1052–1060.Hernandez L.D. et al. Broad Coverage of Genetically Diverse Strains of Clostridium difficile by Actoxumab and Bezlotoxumab Predicted by In Vitro Neutralization and Epitope Modeling // Antimicrob. Agents Chemother. 2015. Vol. 59, № 2. P. 1052–1060.Orrell K.E., Melnyk R.A. Large Clostridial Toxins: Mechanisms and Roles in Disease // Microbiol. Mol. Biol. Rev. 2021. Vol. 85, № 3.Orrell K.E., Melnyk R.A. Large Clostridial Toxins: Mechanisms and Roles in Disease // Microbiol. Mol. Biol. Rev. 2021. Vol. 85, № 3.Lyras D. et al. Toxin B is essential for virulence of Clostridium difficile // Nature. 2009. Vol. 458, № 7242. P. 1176–1179.Lyras D. et al. Toxin B is essential for virulence of Clostridium difficile // Nature. 2009. Vol. 458, № 7242. P. 1176–1179.Drudy D., Fanning S., Kyne L. Toxin A-negative, toxin B-positive Clostridium difficile // Int. J. Infect. Dis. 2007. Vol. 11, № 1. P. 5–10.Drudy D., Fanning S., Kyne L. Toxin A-negative, toxin B-positive Clostridium difficile // Int. J. Infect. Dis. 2007. Vol. 11, № 1. P. 5–10.Lyerly D.M. et al. Effects of Clostridium difficile toxins given intragastrically to animals // Infect. Immun. 1985. Vol. 47, № 2. P. 349–352.Lyerly D.M. et al. Effects of Clostridium difficile toxins given intragastrically to animals // Infect. Immun. 1985. Vol. 47, № 2. P. 349–352.Lee Y. et al. Bezlotoxumab (Zinplava) for Clostridium Difficile Infection: The First Monoclonal Antibody Approved to Prevent the Recurrence of a Bacterial Infection. // P T. 2017. Vol. 42, № 12. P. 735–738.Lee Y. et al. Bezlotoxumab (Zinplava) for Clostridium Difficile Infection: The First Monoclonal Antibody Approved to Prevent the Recurrence of a Bacterial Infection. // P T. 2017. Vol. 42, № 12. P. 735–738.Muyldermans S. Nanobodies: Natural Single-Domain Antibodies // Annu. Rev. Biochem. 2013. Vol. 82, № 1. P. 775–797.Muyldermans S. Nanobodies: Natural Single-Domain Antibodies // Annu. Rev. Biochem. 2013. Vol. 82, № 1. P. 775–797.Koide A. et al. Exploring the Capacity of Minimalist Protein Interfaces: Interface Energetics and Affinity Maturation to Picomolar KD of a Single-domain Antibody with a Flat Paratope // J. Mol. Biol. 2007. Vol. 373, № 4. P. 941–953.Koide A. et al. Exploring the Capacity of Minimalist Protein Interfaces: Interface Energetics and Affinity Maturation to Picomolar KD of a Single-domain Antibody with a Flat Paratope // J. Mol. Biol. 2007. Vol. 373, № 4. P. 941–953.Jovčevska I., Muyldermans S. The Therapeutic Potential of Nanobodies // BioDrugs. 2020. Vol. 34, № 1. P. 11–26.Jovčevska I., Muyldermans S. The Therapeutic Potential of Nanobodies // BioDrugs. 2020. Vol. 34, № 1. P. 11–26.Arbabi-Ghahroudi M., Tanha J., MacKenzie R. Isolation of Monoclonal Antibody Fragments from Phage Display Libraries. 2009. P. 341–364.Arbabi-Ghahroudi M., Tanha J., MacKenzie R. Isolation of Monoclonal Antibody Fragments from Phage Display Libraries. 2009. P. 341–364.De Vos J. et al. Camelid single-domain antibody-fragment engineering for (pre)clinical in vivo molecular imaging applications: adjusting the bullet to its target // Expert Opin. Biol. Ther. 2013. Vol. 13, № 8. P. 1149–1160.De Vos J. et al. Camelid single-domain antibody-fragment engineering for (pre)clinical in vivo molecular imaging applications: adjusting the bullet to its target // Expert Opin. Biol. Ther. 2013. Vol. 13, № 8. P. 1149–1160.Arbabi-Ghahroudi M., Tanha J., MacKenzie R. Prokaryotic expression of antibodies // Cancer Metastasis Rev. 2005. Vol. 24, № 4. P. 501–519.Arbabi-Ghahroudi M., Tanha J., MacKenzie R. Prokaryotic expression of antibodies // Cancer Metastasis Rev. 2005. Vol. 24, № 4. P. 501–519.Dmitriev O.Y., Lutsenko S., Muyldermans S. Nanobodies as Probes for Protein Dynamics in Vitro and in Cells // J. Biol. Chem. 2016. Vol. 291, № 8. P. 3767–3775.Dmitriev O.Y., Lutsenko S., Muyldermans S. Nanobodies as Probes for Protein Dynamics in Vitro and in Cells // J. Biol. Chem. 2016. Vol. 291, № 8. P. 3767–3775.Ackaert C. et al. Immunogenicity Risk Profile of Nanobodies // Front. Immunol. 2021. Vol. 12.Ackaert C. et al. Immunogenicity Risk Profile of Nanobodies // Front. Immunol. 2021. Vol. 12.Unger M. et al. Selection of Nanobodies that Block the Enzymatic and Cytotoxic Activities of the Binary Clostridium Difficile Toxin CDT // Sci. Rep. 2015. Vol. 5, № 1. P. 7850.Unger M. et al. Selection of Nanobodies that Block the Enzymatic and Cytotoxic Activities of the Binary Clostridium Difficile Toxin CDT // Sci. Rep. 2015. Vol. 5, № 1. P. 7850.Greco A. et al. Carbohydrate recognition by Clostridium difficile toxin A // Nat. Struct. Mol. Biol. 2006. Vol. 13, № 5. P. 460–461.Greco A. et al. Carbohydrate recognition by Clostridium difficile toxin A // Nat. Struct. Mol. Biol. 2006. Vol. 13, № 5. P. 460–461.Hussack G. et al. Neutralization of Clostridium difficile Toxin A with Single-domain Antibodies Targeting the Cell Receptor Binding Domain // J. Biol. Chem. 2011. Vol. 286, № 11. P. 8961–8976.Hussack G. et al. Neutralization of Clostridium difficile Toxin A with Single-domain Antibodies Targeting the Cell Receptor Binding Domain // J. Biol. Chem. 2011. Vol. 286, № 11. P. 8961–8976.Murase T. et al. Structural Basis for Antibody Recognition in the Receptor-binding Domains of Toxins A and B from Clostridium difficile // J. Biol. Chem. 2014. Vol. 289, № 4. P. 2331–2343.Murase T. et al. Structural Basis for Antibody Recognition in the Receptor-binding Domains of Toxins A and B from Clostridium difficile // J. Biol. Chem. 2014. Vol. 289, № 4. P. 2331–2343.Yang Z. et al. A Novel Multivalent, Single-Domain Antibody Targeting TcdA and TcdB Prevents Fulminant Clostridium difficile Infection in Mice // J. Infect. Dis. 2014. Vol. 210, № 6. P. 964–972.Yang Z. et al. A Novel Multivalent, Single-Domain Antibody Targeting TcdA and TcdB Prevents Fulminant Clostridium difficile Infection in Mice // J. Infect. Dis. 2014. Vol. 210, № 6. P. 964–972.

The authors declare that there are no conflicts of interest present.